Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-013
- Development stage
- Preclinical
- Lead developer
- ACM Biolabs
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ACM-013 is a preclinical-stage RNA therapeutic candidate being developed by ACM Biolabs. It utilizes the company's proprietary Artificial Cell Membrane (ACM) technology, specifically the ATP-RNA (Artificial Cell Membrane-Tunable Polymer RNA) delivery platform, to facilitate in vivo immune cell engineering. The program is designed to deliver therapeutic RNA payloads directly to immune cells within the patient's body, aiming to reprogram or enhance their function for therapeutic applications. As of early 2026, the program remains in the discovery and preclinical development phase, with a focus on enabling RNA-based therapies through targeted delivery.
Beyond the preview
Go deeper on ACM-013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-013.